Expert Insights

Mary McCormack, MD discusses results from the phase 3 GCIG INTERLACE study evaluating the addition of induction chemotherapy to standard-of-care chemoradiation among patients with advanced cervical cancer.

During the 2023 Lymphoma, Leukemia & Myeloma Congress in New York, Gareth Morgan, MD, examines the role of tumor complexity and microenvironment in the development of multiple myeloma.

In a prospective observational study, approximately 14% of patients with metastatic prostate cancer harbored at least 1 HRR gene alteration, most commonly BRCA.

Aditya Bardia, MD, discusses results from a subgroup analysis of the phase 3 NATALEE study comparing invasive disease-free survival (iDFS) across a broad range of patients with HR-positive, HER2-negative early breast cancer treated with...

Elena Castro, MD, shares final results from the MAGNITUDE study evaluating niraparib plus abiraterone acetate plus prednisone for patients with metastatic castration-resistant prostate cancer and HRR gene alterations.

At the 2023 Lymphoma, Leukemia & Myeloma Congress, Kenneth C. Anderson, MD, discussed existing and promising novel therapies for patients with multiple myeloma.

Antoni Vilaseca, MD, discusses the novel erdafinitib delivery system for patients with non–muscle-invasive bladder cancer (NMIBC) with select FGFR alterations.

Kiran Kumar, MD, MBA, discusses strategies for mitigating tumor burden and risk of transformation for patients with follicular lymphoma, particularly among those with early-stage or limited disease.

Kiran Kumar, MD, MBA, explains study results regarding the potential benefits of re-priming radiation therapy among patients with R/R non-Hodgkin lymphoma, including FL and DLBCL, who experienced incomplete response after CD19-directed CAR...

Abhay Singh, MD, discusses the need for modifications in treatments for older patients with follicular lymphoma or DLBCL who are at risk of transformation to therapy-related myeloid neoplasms or acute myeloid leukemia.